BioCentury
ARTICLE | Company News

Acorda, Mylan reach settlement for Ampyra generic

August 6, 2018 11:03 PM UTC

Acorda Therapeutics Inc. (NASDAQ:ACOR) reached a conditional settlement with Mylan N.V. (NASDAQ:MYL) that would allow Mylan to market a generic version of multiple sclerosis drug Ampyra dalfampridine in the U.S. in 2025 or earlier under certain circumstances, according to an SEC filing Friday.

The news comes after Acorda said late last month that the U.S. Court of Appeals for the Federal Circuit denied the company's injunction to prevent generic competition for Ampyra from entering the market while an appeal of a district court ruling is ongoing (see "Court of Appeals Denies Acorda's Injunction for Ampyra")...